Amarantus Bioscience Holdings Inc., of San Francisco, said it completed the growth and testing components of its confirmatory engineering run, positioning the company to be ready to supply its Engineered Skin Substitute for a planned phase II study of the autologous cell product's use in treating full thickness thermal burns covering more than 50 percent of the body.